Stockreport

Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect [Seeking Alpha]

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF Current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA (2 mg) holding a 63% global market share in 2024. I take a close look at their phase 3 "superior [Read more]